Form 4: Nuvalent Executive Exercises Stock Options, Increasing Holdings

Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc., exercised stock options on January 31, 2025, acquiring 3,120 shares of Class A Common Stock.

Summary

• On January 31, 2025, Henry E. Pelish, the Chief Scientific Officer of Nuvalent, Inc., executed a transaction involving stock options.
• Pelish exercised options to acquire 3,120 shares of Class A Common Stock at a price of $0.87 per share.
• Following this transaction, Pelish directly owns 63,101 shares of Class A Common Stock.
• Pelish also directly owns 2,007 derivative securities.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives, ensuring transparency in insider trading activities.
• Similar filings are made by executives at comparable companies like Relay Therapeutics and Black Diamond Therapeutics when they exercise stock options or trade company shares.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding executive compensation and ownership.

Key Dates

Keywords

Nuvalent, NUVL, stock options, Form 4, insider trading, Henry E. Pelish, Chief Scientific Officer, Class A Common Stock